Preventing glucocorticoid-induced osteoporosis

Area of Science:

• Endocrinology
• Bone Metabolism
• Pharmacology

Background:

• Glucocorticoids are a primary cause of osteoporosis, increasing morbidity in patients with underlying conditions.
• These steroids disrupt calcium metabolism by reducing osteoblast activity and lowering sex hormone levels.
• Rapid bone loss occurs within weeks of glucocorticoid initiation, continuing with long-term use.

Purpose of the Study:

• To review the impact of glucocorticoids on bone health.
• To discuss fracture risk assessment and management strategies for patients on glucocorticoid therapy.

Main Methods:

• Literature review on glucocorticoid-induced osteoporosis.
• Analysis of factors contributing to fracture risk.
• Evaluation of therapeutic interventions for bone density improvement.

Main Results:

• Approximately one-third of patients on glucocorticoids develop fractures, with higher risk in those with low bone density.
• Fracture risk is influenced by age, weight, steroid dose and duration, and prior fracture history.
• Bone density can be improved with sex hormone replacement or bisphosphonates in high-risk individuals.

Conclusions:

• Long-term glucocorticoid therapy necessitates vigilant monitoring of bone health.
• Skeletal assessment and appropriate osteoporosis prophylaxis are essential for at-risk patients.
• While adjunctive therapies exist, their efficacy requires further documentation.